MX9601655A - Proteinas (ob) obesas recombinantes. - Google Patents

Proteinas (ob) obesas recombinantes.

Info

Publication number
MX9601655A
MX9601655A MX9601655A MX9601655A MX9601655A MX 9601655 A MX9601655 A MX 9601655A MX 9601655 A MX9601655 A MX 9601655A MX 9601655 A MX9601655 A MX 9601655A MX 9601655 A MX9601655 A MX 9601655A
Authority
MX
Mexico
Prior art keywords
proteins
recombinant
obese
recombinant obese
hyperlipidaemia
Prior art date
Application number
MX9601655A
Other languages
English (en)
Other versions
MXPA96001655A (es
Inventor
Arthur Campfield
Rene Devos
Yves Guisez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX9601655A publication Critical patent/MX9601655A/es
Publication of MXPA96001655A publication Critical patent/MXPA96001655A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Proteínas que modulan el peso corporal de animales y humanos para el tratamiento, prevencion y control de obesidad y enfermedades o condiciones asociadas, y la expresion recombinante de estas proteínas biologicamente activas en formas purificada y homogénea.
MXPA/A/1996/001655A 1995-05-05 1996-05-03 Proteinas (ob) obesas recombinantes MXPA96001655A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US435777 1982-10-21
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07
US484629 1995-06-07

Publications (2)

Publication Number Publication Date
MX9601655A true MX9601655A (es) 1997-07-31
MXPA96001655A MXPA96001655A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
HRP960213A2 (en) 1997-10-31
SV1996000030A (es) 1999-01-14
GR960300075T1 (en) 1996-12-31
SG49337A1 (en) 1998-05-18
TW464655B (en) 2001-11-21
JPH093098A (ja) 1997-01-07
EP0741187A2 (en) 1996-11-06
PL186568B1 (pl) 2004-01-30
IS4343A (is) 1996-12-09
BG100558A (bg) 1997-03-31
UY24219A1 (es) 2001-03-16
OA10362A (fr) 2001-11-15
EP0741187A3 (es) 1996-12-11
BR9602166A (pt) 1998-01-13
KR960041194A (ko) 1996-12-19
AR003087A1 (es) 1998-07-08
IL118059A0 (en) 1996-08-04
TR199600357A2 (tr) 1996-11-21
PL314051A1 (en) 1996-11-12
ES2093593T1 (es) 1997-01-01
BG62975B1 (bg) 2000-12-29
NO961796D0 (no) 1996-05-03
HU9601120D0 (en) 1996-06-28
AU688210B2 (en) 1998-03-05
KR100219970B1 (ko) 1999-10-01
HU220093B (hu) 2001-10-28
RO117177B1 (ro) 2001-11-30
US6025325A (en) 2000-02-15
DE741187T1 (de) 1997-04-30
SK56996A3 (en) 1997-04-09
NZ286466A (en) 1998-03-25
YU26596A (sh) 1999-03-04
MY132189A (en) 2007-09-28
HUP9601120A2 (en) 1996-11-28
NO961796L (no) 1996-11-06
JP3244627B2 (ja) 2002-01-07
CZ129796A3 (en) 1997-01-15
RU96109211A (ru) 1998-10-27
PE50897A1 (es) 1997-12-19
MA23856A1 (fr) 1996-12-31
TNSN96066A1 (fr) 2005-03-15
HUP9601120A3 (en) 1999-07-28
AU5197896A (en) 1996-11-14
CA2175298A1 (en) 1996-11-06
CN1157290A (zh) 1997-08-20

Similar Documents

Publication Publication Date Title
MY132189A (en) Recombinant obese (ob) proteins
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
AU3372595A (en) Biologically active fragments of glucagon-like insulinotropic peptide
BG101392A (en) Method of treating diabetes mellitus using kgf
NO940436D0 (no) Forlenget avgivelse av peptider
CA2064689A1 (en) Stabilized protein or peptide conjugates
EP1244708B8 (en) Method for treating inflammation
EP0926159A3 (en) Glucagon-like peptide-1 crystals
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AU4863797A (en) Use of glp-1 peptides
EP0906310A4 (en) OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY
CA2072624A1 (en) Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
WO2003000242A3 (en) Method for the treatment of lymphedema using guaifenesin
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
AU1384995A (en) Human circulating cytokine cc-1
WO2002070546A3 (en) Modified derivatives of cck-8
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
AU5732190A (en) Glycoprotein hormone receptor molecules
MX9803662A (es) Oligopeptidos novedosos, preparacion y uso de estos.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AU2415599A (en) Rantes mutants and therapeutic applications thereof
WO1999053064A3 (en) Methods of delivering glp-1

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees